Evidence map›Paper›PMID 22705040›Full record

SynthesisBiological psychiatry2012

Ketamine for depression: where do we go from here?

Marije Aan Het Rot, Carlos A Zarate, Dennis S Charney, Sanjay J Mathew

3 registry-linked trialsOpen access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biological psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 162 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
162citing papers in PubMed, 11 pooled it
44.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02397356 phase4withdrawnnot on this mapstarted 2018, after this paper: background citation

Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia

TypeinterventionalSponsorTampere University HospitalRan2018 to 2020Enrolled0ConditionsPain, PostoperativeArmsKetamine first AB, Placebo first BA
NCT02593643 early_phase1completednot on this mapstarted 2016, after this paper: background citation

A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2016 to 2017Enrolled9ConditionsMajor Depressive Disorder, Bipolar I Disorder, Bipolar II Disorder, Bipolar DepressionArmsKetamine, Midazolam, Treatment as usual (TAU)
NCT03336541 phase4completednot on this mapstarted 2017, after this paper: background citation

Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: Blind Test, Randomized, Placebo-controlled Trial

TypeinterventionalSponsorPeking University First HospitalRan2017 to 2018Enrolled64ConditionsPerinatal Depression, Ketamine, Cesarean Delivery, Postpartum DepressionArmsKetamine, Placebo
3 · Its place in the literature

Who cites it

162 citing papers in PubMed, 11 syntheses or guidelines pooled it, 413 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines.The international journal of neuropsychopharmacology · 2020
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Journal of the American Academy of Child and Adolescent Psychiatry · 2015
    Pooled it
  10. Pooled it
  11. Pooled it
  12. Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression.Journal of child and adolescent psychopharmacology · 2024
    Trial
  13. Trial
  14. Trial
  15. Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial
  20. Temporal Dynamics of Antidepressant Ketamine Effects on Glutamine Cycling Follow Regional Fingerprints of AMPA and NMDA Receptor Densities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial

102 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Marije Aan Het RotDepartment of Psychology and School of Behavioral and Cognitive Neuroscience, University of Groningen, The Netherlands. m.aan.het.rot@rug.nl
Carlos A Zarate
Dennis S Charney
Sanjay J Mathew
Icahn School of Medicine at Mount Sinai · USMichael E. DeBakey VA Medical Center · USNational Institute of Mental Health · USUniversity of Groningen · NL

Funding

Glutamatergic Modulators for Rapid & Sustained Antidepressant EffectZIAMH002857 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2025
$55.0M
Optimization of IV Ketamine for Treatment Resistant Major DepressionR01MH081870 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MATHEW, SANJAY J · 2009 to 2012
$1.4M
Intramural NIH HHS ZIA MH002857NIMH NIH HHS R01 MH081870NIMH NIH HHS R01MH81870
6 · The paper itself

Abstract

Since publication of the first randomized controlled trial describing rapid antidepressant effects of ketamine, several reports have confirmed the potential utility of this dissociative anesthetic medication for treatment of major depressive episodes, including those associated with bipolar disorder and resistant to other medications and electroconvulsive therapy. These reports have generated several questions with respect to who might respond to ketamine, how, and for how long. To start answering these questions. We used PubMed.gov and ClinicalTrials.gov to perform a systematic review of all available published data on the antidepressant effects of ketamine and of all recently completed, ongoing, and planned studies. To date, 163 patients, primarily with treatment-resistant depression, have participated in case studies, open-label investigations, or controlled trials. All controlled trials have used a within-subject, crossover design with an inactive placebo as the control. Ketamine administration has usually involved an anaesthesiologist infusing a single, subanesthetic, intravenous dose, and required hospitalization for at least 24 hours postinfusion. Response rates in the open-label investigations and controlled trials have ranged from 25% to 85% at 24 hours postinfusion and from 14% to 70% at 72 hours postinfusion. Although adverse effects have generally been mild, some patients have experienced brief changes in blood pressure, heart rate, or respiratory rate. Risk-benefit analyses support further research of ketamine for individuals with severe mood disorders. However, given the paucity of randomized controlled trials, lack of an active placebo, limited data on long-term outcomes, and potential risks, ketamine administration is not recommended outside of the hospital setting.

Indexed as

AnimalsAntidepressive AgentsDatabases, FactualDepressionHumansKetamineAntidepressive AgentsKetamine

Identifiers

PMID22705040
PMCPMC3438349
OpenAlexW2044325416

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.